← Impact Biomedical (IBO)

Impact Biomedical SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

  • 8-KNov. 18, 2026, 10:06 a.m. ETView on SEC.govOur explainer

    Completion of acquisition or disposition of assets · Delisting notice / failure to meet listing standard · Material modification of security holders' rights · Change in control · Departure/appointment of directors or officers · Amendments to articles or bylaws; fiscal year change · Financial statements and exhibits

    AI summary, unreviewedImpact BioMedical Inc. completes reverse merger into Cayman-incorporated PubCo, delists from NYSE American, and shareholders are left with a 4.80% stake

  • 8-KNov. 17, 2026, 4:05 p.m. ETView on SEC.gov

    Submission of matters to a vote of security holders

    AI summary, unreviewedImpact Biomedical Inc. stockholders approve Zoar merger agreement and director slate at November 13, 2026 special meeting

  • 8-KNov. 3, 2026, 9:15 a.m. ETView on SEC.gov

    Regulation FD disclosure · Financial statements and exhibits

    AI summary, unreviewedImpact Biomedical Announces SEC Effectiveness of Form F-4 for Zoar Business Combination; Stockholder Vote Set for November 13, 2026

  • 8-KOct. 9, 2026, 4:58 p.m. ETView on SEC.gov

    Amendments to articles or bylaws; fiscal year change · Financial statements and exhibits

    AI summary, unreviewedImpact BioMedical Inc. Effects 1-for-12.62 Reverse Stock Split, Cutting Shares Outstanding From About 107.8 Million to About 8.6 Million

  • 8-KSept. 16, 2026, 6:05 p.m. ETView on SEC.gov

    Regulation FD disclosure · Financial statements and exhibits

  • 8-KSept. 14, 2026, 7:43 p.m. ETView on SEC.gov

    Regulation FD disclosure · Financial statements and exhibits